Try our mobile app

Switch to company model in classical logic    *

General information

Country: DENMARK

Sector: Biotechnology

Genmab A/S operates as a biotechnology company. The Company specializes in development of antibody therapeutics for the treatment of cancer. Genmab serves customers worldwide.
Website: genmab.com



Growth: Good revenue growth rate 16.8%, there is slowdown compared to average historical growth rates 39.3%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +35.7%. On average the margin is decreasing unsteadily. Gross margin is high, +95.1%. In the last quarter the company did not beat the estimated EPS, -92.2%. The company was ahead of estimated EPS in 0% of quarters (showing a gain of -$1.34 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -1.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 210.3% higher than minimum and 2.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.7x by EV / Sales multiple , the company can be 58.7% overvalued

Key Financials (Download financials)

Ticker: GMAB
Share price, USD:  (+4.0%)55.8
year average price 32.79  


year start price 30.31 2025-11-11

min close price 23.85 2026-06-02

max close price 57.29 2026-10-28

current price 55.80 2026-11-10
Common stocks: 653 836 087

Dividend Yield:  0.0%
FCF Yield LTM: -1.8%
EV / LTM EBITDA: 32.1x
EV / EBITDA annualized: 30.2x
Last revenue growth (y/y):  +16.8%
Last growth of EBITDA (y/y):  -5.5%
Historical revenue growth:  +39.3%
Historical growth of EBITDA:  +43.3%
EV / Sales: 11.5x
Margin (EBITDA LTM / Revenue): 35.7%
Fundamental value created in LTM:
Market Cap ($m): 36 484
Net Debt ($m): -842
EV (Enterprise Value): 35 642
Price to Book: 6.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-29globenewswire.com

Grant of Restricted Stock Units and Warrants to Employees in Genmab

2026-01-16reuters.com

Genmab's blood cancer drug fails main goal in late-stage study

2026-01-16businesswire.com

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

2026-01-16globenewswire.com

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

2026-01-14seekingalpha.com

Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-29businesswire.com

Genmab Portfolio Prioritization Update

2025-12-29globenewswire.com

Genmab Portfolio Prioritization Update

2025-12-12businesswire.com

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

2025-12-12globenewswire.com

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

2025-12-11globenewswire.com

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB
reportedCurrency USD DKK DKK DKK DKK DKK DKK DKK DKK DKK DKK DKK DKK DKK
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-02 2023-11-07 2023-08-03 2023-05-10 2022-09-30
acceptedDate 2025-11-06 11:11:39 2025-08-07 11:38:58 2025-02-12 13:06:30 2024-11-06 11:11:00 2024-08-08 11:14:11 2024-05-02 11:08:52 2024-02-14 13:49:51 2023-11-07 11:12:38 2023-08-03 11:16:46 2023-05-10 11:23:53 2023-02-22 12:55:34 2022-09-29 20:00:00 2022-02-16 13:56:43 2021-03-29 11:07:38
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 022M 5 862M 21 526M 5 540M 5 402M 4 143M 16 474M 4 744M 4 198M 2 854M 14 505M 4 087M 8 417M 10 111M
costOfRevenue 58M 361M 985M 273M 190M 185M 226M 100M 0 0 0 0 0 0
grossProfit 964M 5 501M 20 541M 5 267M 5 212M 3 958M 16 248M 4 644M 4 198M 2 854M 14 505M 4 087M 8 417M 10 111M
grossProfitRatio 0.943 0.938 0.951 0.965 0.955 0.979 1 1 1
researchAndDevelopmentExpenses 357M 2 307M 9 748M 2 283M 2 502M 2 300M 7 630M 2 088M 1 853M 1 741M 5 562M 1 486M 4 181M 3 137M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 661M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 148M 913M 3 790M 865M 894M 857M 3 297M 839M 848M 676M 2 676M 670M 1 283M 661M
otherExpenses 0 0 300M 17M 0 0 0 0 0 0 0 0 0 0
operatingExpenses 505M 3 219M 13 838M 3 165M 3 396M 3 157M 10 927M 2 927M 2 701M 2 417M 8 238M 2 156M 5 464M 3 798M
costAndExpenses 563M 3 580M 14 823M 3 438M 3 762M 3 342M 11 153M 3 027M 2 701M 2 417M 8 238M 2 156M 5 464M 3 798M
interestIncome 32M 158M 995M 162M 292M 295M 939M 243M 209M 192M 324M 97M 197M 184M
interestExpense 3M 57M 120M 18M 19M 7M 27M 8M 7M 6M 21M 6M 13M 10M
depreciationAndAmortization 18M 101M 413M 112M 69M 60M 240M 243M 209M 192M 362M 1 347M 250M 246M
ebitda 503M 2 839M 9 697M 1 849M 2 146M 1 096M 5 947M 1 960M 1 706M 629M 7 346M 2 028M 4 181M 6 160M
ebitdaratio 0.492 0.484 0.334 0.397 0.265 0.413 0.406 0.22 0.496
operatingIncome 459M 2 281M 6 703M 2 102M 1 816M 801M 5 321M 1 717M 1 497M 437M 6 267M 681M 2 953M 6 313M
operatingIncomeRatio 0.449 0.389 0.379 0.336 0.193 0.362 0.357 0.153 0.167
totalOtherIncomeExpensesNet 23M 399M 2 461M -383M 311M 915M 316M 750M 24M -151M 678M 2 591M 965M -409M
incomeBeforeTax 482M 2 681M 9 164M 1 719M 2 127M 1 716M 5 637M 2 702M 1 723M 286M 6 945M 3 272M 3 918M 5 904M
incomeBeforeTaxRatio 0.472 0.457 0.31 0.394 0.414 0.57 0.41 0.1 0.801
incomeTaxExpense 81M 551M 1 320M 453M 719M 391M 1 285M 573M 366M 60M 1 493M 690M 961M 1 146M
netIncome 401M 2 129M 7 844M 1 266M 1 408M 1 325M 4 352M 2 129M 1 357M 226M 5 452M 2 582M 2 957M 4 758M
netIncomeRatio 0.392 0.363 0.229 0.261 0.32 0.449 0.323 0.079 0.632
eps 0.65 3.45 12.14 19.51 21.7 2.03 6.6 32.6 2.08 0.35 8.34 3.96 4.52 7.3
epsdiluted 0.65 3.42 1.95 2.17 2.02 32.32 2.06 0.34 3.92
weightedAverageShsOut 616M 618M 646M 65M 65M 653M 659M 65M 652M 660M 654M 653M 654M 652M
weightedAverageShsOutDil 621M 620M 646M 649M 649M 657M 659M 66M 658M 660M 660M 659M 660M 659M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-12 2024-02-14 2023-02-22 2022-02-16 2021-03-29
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 875M 912M 303M 184M 174M
ebit 9 284M 5 707M 6 966M 3 931M 5 914M
nonOperatingIncomeExcludingInterest -2 581M -386M -699M -978M 399M
netIncomeFromContinuingOperations 7 844M 4 352M 5 452M 2 957M 4 758M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 7 844M 4 352M 5 452M 2 957M 4 758M
epsDiluted 12.14 6.6 8.26 4.48 7.22

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB
reportedCurrency USD DKK DKK DKK DKK DKK DKK DKK DKK USD DKK DKK DKK DKK
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-02 2023-11-07 2023-08-03 2023-05-10 2022-09-30
acceptedDate 2025-11-06 11:11:39 2025-08-07 11:38:58 2025-02-12 13:06:30 2024-11-06 11:11:00 2024-08-08 11:14:11 2024-05-02 11:08:52 2024-02-14 13:49:51 2023-11-07 11:12:38 2023-08-03 11:16:46 2023-05-10 11:23:53 2023-02-22 12:55:34 2022-09-29 20:00:00 2022-02-16 13:56:43 2021-03-29 11:07:38
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 761M 8 213M 9 858M 6 342M 4 331M 14 670M 14 867M 14 273M 10 874M 12 288M 9 893M 10 377M 8 957M 7 260M
shortTermInvestments 1 650M 10 158M 11 243M 10 976M 11 402M 14 914M 13 268M 13 252M 14 010M 12 256M 12 431M 13 411M 10 381M 8 819M
cashAndShortTermInvestments 3 411M 18 371M 21 101M 17 318M 15 733M 29 584M 28 135M 27 525M 24 884M 24 544M 22 324M 23 788M 19 338M 16 079M
netReceivables 1 046M 6 324M 6 691M 6 310M 6 168M 4 679M 4 947M 5 432M 4 814M 3 687M 5 712M 4 951M 3 367M 2 463M
inventory 14M 82M 62M 71M 36M 106M 57M 70M 51M 0 0 0 0 0
otherCurrentAssets 0 0 0 0 0 0 0 0 0 0 182M 0 31M 249M
totalCurrentAssets 4 471M 24 778M 27 854M 23 699M 21 937M 34 369M 33 139M 33 027M 29 749M 28 231M 28 218M 28 739M 22 736M 18 791M
propertyPlantEquipmentNet 266M 1 755M 264M 1 801M 1 880M 1 860M 1 641M 1 651M 1 634M 1 596M 1 322M 1 289M 975M 736M
goodwill 355M 2 250M 2 535M 2 407M 2 518M 0 0 0 0 0 0 0 0 0
intangibleAssets 1 748M 11 102M 12 343M 11 504M 12 011M 23M 101M 115M 0 0 146M 0 254M 338M
goodwillAndIntangibleAssets 2 103M 13 352M 14 878M 13 911M 14 529M 23M 101M 115M 129M 132M 146M 200M 254M 338M
longTermInvestments 36M 222M 228M 189M 273M 216M 134M 156M 183M 140M 133M 155M 371M 1 081M
taxAssets 127M 805M 127M 0 0 212M 212M 252M 252M 252M 0 264M 0 0
otherNonCurrentAssets 18M 51M 2 460M 60M 0 0 62M 37M 31M 43M 300M 39M 291M 197M
totalNonCurrentAssets 2 550M 16 185M 17 957M 15 961M 16 682M 2 311M 2 150M 2 211M 2 229M 2 163M 1 901M 1 947M 1 891M 2 352M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 7 021M 40 962M 45 811M 39 660M 38 619M 36 680M 35 289M 35 238M 31 978M 30 394M 30 119M 30 686M 24 627M 21 143M
accountPayables 0 0 0 0 0 2 512M 0 2 341M 0 0 0 0 350M 0
shortTermDebt 16M 101M 0 91M 94M 92M 0 83M 82M 89M 0 79M 0 0
taxPayables 120M 40M 1 710M 1 273M 837M 122M 54M 445M 0 0 0 948M 0 0
deferredRevenue 3M 38M 24M 39M 33M 33M 33M 33M 33M 33M 0 33M 0 0
otherCurrentLiabilities 602M 3 807M 0 3 182M 3 400M 122M 0 445M 1 878M 1 833M 1 749M 2 876M 860M 1 211M
totalCurrentLiabilities 741M 3 986M 5 308M 4 585M 4 364M 2 759M 2 484M 2 902M 1 993M 1 955M 1 823M 2 988M 1 568M 1 253M
longTermDebt 126M 836M 0 896M 925M 918M 0 710M 721M 740M 0 550M 0 0
deferredRevenueNonCurrent 67M 425M 480M 466M 0 480M 480M 480M 480M 480M 0 480M 0 0
deferredTaxLiabilitiesNonCurrent 330M 2 091M 2 359M 1 762M 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 6M 25M 30M 29M 2 361M 26M 35M 34M 29M 29M 491M 929M 500M 492M
totalNonCurrentLiabilities 529M 3 378M 3 806M 3 153M 3 286M 1 424M 1 195M 1 224M 1 230M 1 249M 1 014M 1 041M 863M 769M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 142M 938M 1 029M 987M 1 019M 918M 770M 793M 803M 829M 597M 629M 425M 319M
totalLiabilities 1 270M 7 364M 9 114M 7 738M 7 650M 4 183M 3 679M 4 126M 3 223M 3 204M 2 837M 4 029M 2 431M 2 022M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 10M 63M 66M 66M 66M 66M 66M 66M 66M 66M 66M 66M 66M 66M
retainedEarnings 4 032M 22 801M 23 551M 19 623M 18 133M 19 803M 19 023M 18 452M 16 165M 14 666M 14 809M 14 299M 10 020M 7 107M
accumulatedOtherComprehensiveIncomeLoss -204M -1 331M 490M -346M 234M 108M 60M 142M 112M 117M 98M 151M 81M 54M
othertotalStockholdersEquity 1 913M 12 066M 12 579M 12 536M 12 520M 12 452M 12 412M 12 341M 12 141M
totalStockholdersEquity 5 751M 33 599M 36 697M 31 922M 30 969M 32 497M 31 610M 31 112M 28 755M 27 190M 27 282M 26 657M 22 196M 19 121M
totalEquity 5 751M 33 599M 36 697M 31 922M 30 969M 32 497M 31 610M 31 112M 28 755M 27 190M 27 282M 26 657M 22 196M 19 121M
totalLiabilitiesAndStockholdersEquity 7 021M 40 962M 39 660M 38 619M 36 680M 35 238M 31 978M 30 394M 30 686M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7 021M 40 962M 45 811M 39 660M 38 619M 36 680M 35 289M 35 238M 31 978M 30 394M 30 119M 30 686M 24 627M 21 143M
totalInvestments 1 686M 10 380M 11 471M 11 165M 11 675M 15 130M 13 402M 13 408M 14 193M 12 396M 12 564M 13 566M 10 752M 9 900M
totalDebt 142M 938M 1 029M 987M 1 019M 1 010M 770M 793M 803M 829M 597M 629M 425M 319M
netDebt -1 619M -7 275M -8 829M -5 355M -3 312M -13 660M -14 097M -13 480M -10 071M -11 459M -9 296M -9 748M -8 532M -6 941M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-12 2024-02-14 2023-02-22 2022-02-16 2021-03-29
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 6 590M 4 947M 5 712M 3 367M 2 463M
otherReceivables 101M 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 5 192M 2 361M 0 350M 0
otherPayables 5 192M 2 361M 0 0 0
accruedExpenses 0 0 0 296M 0
capitalLeaseObligationsCurrent 92M 90M 74M 62M 42M
capitalLeaseObligationsNonCurrent 937M 680M 523M 363M 277M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 12 590M 12 461M 12 309M 12 029M 11 894M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB GMAB
reportedCurrency USD DKK DKK DKK DKK DKK DKK DKK DKK DKK DKK DKK DKK DKK
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-02 2023-11-07 2023-08-03 2023-05-10 2022-09-30
acceptedDate 2025-11-06 11:11:39 2025-08-07 11:38:58 2025-02-12 13:06:30 2024-11-06 11:11:00 2024-08-08 11:14:11 2024-05-02 11:08:52 2024-02-14 13:49:51 2023-11-07 11:12:38 2023-08-03 11:16:46 2023-05-10 11:23:53 2023-02-22 12:55:34 2022-09-29 20:00:00 2022-02-16 13:56:43 2021-03-29 11:07:38
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 482M 2 681M 7 844M 1 719M 1 408M 1 325M 5 637M 2 702M 1 723M 286M 7 035M 3 272M 3 983M 4 758M
depreciationAndAmortization 18M 101M 413M 112M 164M 22M 295M 22M 0 0 362M 0 248M 266M
deferredIncomeTax 0 0 0 0 0 0 122M -184M 0 0 0 0 -546M 0
stockBasedCompensation 34M 209M 721M 186M 0 168M 586M 162M 0 0 439M 0 310M 200M
changeInWorkingCapital 2M -665M -1 595M -524M -689M 419M 1 362M -137M -1 496M 2 837M -1 930M -275M -770M 306M
accountsReceivables -47M -1 274M -1 590M -285M 0 0 797M 0 0 0 -2 123M 0 -1 074M 306M
inventory -1 000 000 -6M -5M -34M 0 0 -57M 0 0 0 0 0 0 0
accountsPayables 0 0 0 0 0 0 622M 0 0 0 283M 0 304M 0
otherWorkingCapital 50M 615M 0 -205M -689M 419M 0 -137M 0 0 -90M 0 0 0
otherNonCashItems 0 -1 933M 388M 540M 630M -231M -622M -528M 209M 112M -1 994M -1 029M -997M 903M
netCashProvidedByOperatingActivities 536M 393M 7 771M 2 033M 1 513M 1 513M 7 380M 2 037M 436M 3 235M 3 912M 1 968M 2 228M 6 433M
investmentsInPropertyPlantAndEquipment -2M -63M -187M -38M -27M -28M -366M -98M -107M -104M -317M -82M -252M -307M
acquisitionsNet 0 0 -12 246M 0 -12 246M 0 0 -1 106M 10M 0 2 444M 0 709M 0
purchasesOfInvestments -387M -1 901M -8 636M -1 894M -716M -4 554M -10 907M -1 272M -4 251M -2 876M -9 698M -3 185M -15 616M 0
salesMaturitiesOfInvestments 335M 2 129M 11 279M 2 087M 4 296M 3 141M 10 001M 2 378M 2 523M 2 967M 7 254M 1 885M 14 907M 0
otherInvestingActivites 0 0 69M -79M -1 413M 1 106M -10M 0 0
netCashUsedForInvestingActivites -54M 165M 224M -8 772M -1 441M 1 008M -1 835M -13M -1 382M
debtRepayment -5M -25M -17M -19M -24M -16M -29M -21M -17M
commonStockIssued 0 0 0 0 59M 40M 0 0 0
commonStockRepurchased -24M -2 573M -3 988M -294M -3 040M -545M -564M -4M -21M -543M -908M -697M -447M -25M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 8M 25M 35M 8M -85M 36M 57M -47M 72M
netCashUsedProvidedByFinancingActivities -21M -2 573M -276M -3 051M -595M 20M 7M -611M -642M
effectOfForexChangesOnCash 4M -32M 1 046M 30M -29M 326M -518M 334M -22M -216M 574M 617M 850M -445M
netChangeInCash 465M -2 047M -5 009M 2 011M -10 339M -197M 4 974M 3 399M -1 414M 2 395M 936M 561M 1 697M 3 708M
cashAtEndOfPeriod 1 761M 8 213M 9 858M 6 342M 4 331M 14 670M 14 867M 14 273M 10 874M 12 288M 9 893M 10 377M 8 957M 7 260M
cashAtBeginningOfPeriod 1 296M 10 260M 14 867M 4 331M 14 670M 14 867M 9 893M 10 874M 12 288M 9 893M 8 957M 9 816M 7 260M 3 552M
operatingCashFlow 536M 393M 7 771M 2 033M 1 513M 1 513M 7 380M 2 037M 436M 3 235M 3 912M 1 968M 2 228M 6 433M
capitalExpenditure -2M -63M -187M -48M -27M -28M -376M -98M -107M -104M -317M -82M -252M -307M
freeCashFlow 534M 330M 7 584M 1 985M 1 486M 1 485M 7 004M 1 939M 329M 3 131M 3 595M 1 886M 1 976M 6 126M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-12 2024-02-14 2023-02-22 2022-02-16 2021-03-29
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -117M -10M -2 444M -709M -2 044M
netCashProvidedByInvestingActivities -9 907M -1 282M -2 761M -961M -2 351M
netDebtIssuance -60M -91M -73M -58M -44M
longTermNetDebtIssuance -60M -91M -73M -58M -44M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -3 988M -564M -908M -447M -25M
netCommonStockIssuance -3 988M -564M -908M -447M -25M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 129M 49M 192M 85M 140M
netCashProvidedByFinancingActivities -3 919M -606M -789M -420M 71M
incomeTaxesPaid 0 0 0 0 0
interestPaid 35M 0 0 0 20M

Earning call transcript

2025 q3
2025-11-08 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-14 ET (fiscal 2024 q4)
2024 q3
2024-11-09 ET (fiscal 2024 q3)
2024 q2
2024-08-12 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-10 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-09 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-08-06 ET
Genmab Announces Financial Results for the First Half of 2026
2026-07-23 ET
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2026-07-15 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
2026-07-06 ET
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
2026-06-29 ET
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
2026-06-29 ET
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
2026-06-15 ET
Major Shareholder Announcement
2026-06-13 ET
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2026-06-11 ET
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
2026-05-21 ET
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
2026-05-08 ET
Major Shareholder Announcement
2026-05-07 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2026
2026-04-14 ET
Major Shareholder Announcement
2026-04-14 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
2026-04-13 ET
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
2026-04-01 ET
Major Shareholder Announcement
2026-03-30 ET
Major Shareholder Announcement
2026-02-17 ET
Genmab Publishes 2025 Annual Report
2026-01-30 ET
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
2026-01-21 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
2026-01-16 ET
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2026-01-16 ET
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2026-01-07 ET
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
2025-12-29 ET
Genmab Portfolio Prioritization Update
2025-12-29 ET
Genmab Portfolio Prioritization Update
2025-12-12 ET
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
2025-12-12 ET
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
2025-12-08 ET
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
2025-12-07 ET
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R²) in Patients with Relapsed or Refractory Follicular Lymphoma
2025-12-06 ET
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
2025-11-19 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2025-11-18 ET
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
2025-11-18 ET
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
2025-11-06 16:02 ET
Genmab Announces Financial Results for the Nine Months of 2025
2025-11-03 ET
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
2025-10-18 ET
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
2025-10-14 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
2025-09-29 ET
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
2025-09-29 ET
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
2025-09-23 ET
Major Shareholder Announcement
2025-09-03 ET
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2025-08-26 ET
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
2025-08-07 ET
Genmab Announces Financial Results for the First Half of 2025
2025-08-07 ET
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
2025-08-07 ET
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
2025-07-16 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
2025-07-01 ET
Genmab Announces Changes to its Executive Committee
2025-06-15 ET
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
2025-06-02 ET
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
2025-05-22 ET
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
2025-05-14 ET
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
2025-05-08 ET
Genmab Announces Financial Results for the First Quarter of 2024
2025-05-01 ET
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R²) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2025-05-01 ET
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2025-04-15 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
2025-03-31 ET
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
2025-03-27 ET
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
2025-03-21 ET
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
2025-03-17 ET
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
2025-03-10 ET
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
2025-03-10 ET
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
2025-02-20 ET
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
2025-02-12 ET
Genmab Publishes 2024 Annual Report
2025-01-22 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
2024-12-09 ET
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
2024-12-08 ET
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
2024-12-07 ET
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
2024-11-06 16:01 ET
Genmab Announces Financial Results for the First Nine Months of 2024
2024-10-15 10:25 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
2024-10-04 17:55 ET
Major Shareholder Announcement
2024-09-15 12:45 ET
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
2024-08-19 18:00 ET
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
2024-08-19 18:00 ET
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
2024-06-28 06:00 ET
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
2024-06-28 06:00 ET
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
2024-06-26 23:08 ET
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
2024-06-03 13:00 ET
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
2024-06-02 21:30 ET
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
2024-05-23 21:00 ET
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
2024-05-21 15:10 ET
Genmab Completes Acquisition of ProfoundBio
2024-05-21 15:06 ET
Genmab Completes Acquisition of ProfoundBio
2024-05-14 14:05 ET
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
2024-05-02 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2024
2024-04-29 22:40 ET
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
2024-04-03 05:35 ET
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
2024-04-03 05:34 ET
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
2024-02-27 12:45 ET
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
2024-02-14 16:41 ET
Genmab Announces Initiation of Share Buy-Back Program
2024-02-14 16:02 ET
Genmab Publishes 2023 Annual Report
2024-02-02 11:45 ET
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
2023-12-09 17:00 ET
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
2023-11-27 12:00 ET
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
2023-11-08 16:09 ET
Major Shareholder Announcement
2023-11-07 16:01 ET
Genmab Announces Financial Results for the First Nine Months of 2023
2023-11-02 13:05 ET
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
2023-10-17 10:22 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
2023-09-25 11:45 ET
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-09-25 11:45 ET
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-09-25 09:55 ET
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2023-09-04 19:00 ET
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
2023-08-03 15:01 ET
Genmab Announces Financial Results for the First Half of 2023
2023-08-03 15:01 ET
Genmab Announces Financial Results for the First Half of 2023
2023-07-27 22:01 ET
Genmab Updates 2023 Financial Guidance
2023-07-27 22:01 ET
Genmab Updates 2023 Financial Guidance
2023-07-21 08:30 ET
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-07-21 08:30 ET
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-07-21 08:30 ET
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-07-20 10:22 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
2023-07-20 10:22 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
2023-06-27 22:50 ET
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2023-06-27 22:49 ET
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2023-06-27 22:49 ET
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2023-06-22 11:00 ET
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
2023-06-22 11:00 ET
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
2023-06-20 18:45 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2023-06-09 07:01 ET
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
2023-06-09 07:01 ET
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
2023-06-08 21:22 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2023-06-06 06:00 ET
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-31 12:15 ET
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
2023-05-25 21:10 ET
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
2023-05-25 21:10 ET
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
2023-05-23 19:14 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2023-05-19 16:38 ET
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-05-19 16:33 ET
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-05-19 16:33 ET
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-05-10 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2023
2023-05-10 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2023
2023-04-24 08:39 ET
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
2023-04-24 08:39 ET
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
2023-04-20 23:45 ET
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
2023-04-20 23:45 ET
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
2023-04-18 10:25 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
2023-04-18 10:25 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
2023-04-17 06:00 ET
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
2023-04-17 06:00 ET
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
2023-04-17 06:00 ET
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
2023-04-03 14:12 ET
Completion of share buy-back program
2023-03-29 20:19 ET
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
2023-03-29 20:10 ET
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
2023-03-29 13:53 ET
Passing of Genmab A/S’ Annual General Meeting
2023-03-28 06:00 ET
Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer
2023-03-27 13:00 ET
Transactions in connection with share buy-back program
2023-03-13 11:18 ET
Transactions in connection with share buy-back program
2023-02-28 19:54 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2023-02-27 16:21 ET
Transactions in connection with share buy-back program
2023-02-24 20:32 ET
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
2023-02-23 11:00 ET
Notice to Convene the Annual General Meeting of Genmab A/S
2023-02-22 20:45 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2023-02-22 18:11 ET
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
2023-02-22 16:12 ET
Genmab Announces Initiation of Share Buy-Back Program
2023-02-22 16:12 ET
Genmab Announces Initiation of Share Buy-Back Program
2023-02-22 16:01 ET
Genmab Publishes 2022 Annual Report
2023-02-22 16:01 ET
Genmab Publishes 2022 Annual Report
2023-01-24 19:00 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2023-01-24 11:27 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
2023-01-24 11:27 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
2023-01-19 16:00 ET
Correction to Company Announcement No. 1 of January 3, 2023
2023-01-03 17:31 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2023-01-02 12:56 ET
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-21 12:00 ET
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-12-21 12:00 ET
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-12-13 20:05 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-12-13 19:58 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-12-12 13:23 ET
Genmab to Hold 2022 R&D Update and ASH Data Review Meeting
2022-12-11 22:30 ET
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
2022-12-11 22:30 ET
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
2022-11-23 19:56 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-11-21 19:44 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-11-21 19:39 ET
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
2022-11-21 13:00 ET
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-11-21 13:00 ET
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-11-15 18:54 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-11-14 17:30 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-11-10 13:27 ET
Genmab to Present at Jefferies London Healthcare Conference
2022-11-09 16:01 ET
Genmab Announces Financial Results for the First Nine Months of 2022
2022-11-09 16:01 ET
Genmab Announces Financial Results for the First Nine Months of 2022
2022-11-03 16:45 ET
Genmab Improves Its 2022 Financial Guidance
2022-11-03 16:45 ET
Genmab Improves Its 2022 Financial Guidance
2022-11-03 13:01 ET
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
2022-11-03 13:01 ET
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
2022-10-28 12:45 ET
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
2022-10-28 12:45 ET
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
2022-10-18 10:35 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
2022-10-18 10:35 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
2022-10-05 19:56 ET
Major Shareholder Announcement
2022-10-05 19:56 ET
Major Shareholder Announcement
2022-09-27 16:43 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-09-20 19:20 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2022-09-06 14:53 ET
Genmab to Present at Morgan Stanley 20th Annual Global Healthcare Conference
2022-09-01 16:27 ET
Completion of share buy-back program
2022-08-29 09:04 ET
Transactions in connection with share buy-back program
2022-08-16 18:26 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-08-16 18:22 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-08-15 07:42 ET
Transactions in connection with share buy-back program
2022-08-10 15:01 ET
Genmab Announces Financial Results for the First Half of 2022
2022-08-10 15:01 ET
Genmab Announces Financial Results for the First Half of 2022
2022-08-08 16:33 ET
Genmab Improves Its 2022 Financial Guidance
2022-08-08 16:33 ET
Genmab Improves Its 2022 Financial Guidance
2022-08-05 10:45 ET
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
2022-08-02 18:46 ET
Major Shareholder Announcement
2022-07-25 11:49 ET
Transactions in connection with share buy-back program
2022-07-20 17:03 ET
Major Shareholder Announcement
2022-07-20 17:03 ET
Major Shareholder Announcement
2022-07-19 10:33 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
2022-07-19 10:33 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
2022-07-18 14:05 ET
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2022-07-18 14:01 ET
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2022-07-18 14:01 ET
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2022-07-11 15:28 ET
Major Shareholder Announcement
2022-07-11 08:50 ET
Transactions in connection with share buy-back program
2022-07-05 18:05 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-07-01 14:14 ET
Major Shareholder Announcement
2022-07-01 14:14 ET
Major Shareholder Announcement
2022-06-30 18:24 ET
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-06-30 18:24 ET
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-06-27 08:09 ET
Transactions in connection with share buy-back program
2022-06-23 15:55 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-06-20 14:35 ET
Major Shareholder Announcement
2022-06-20 14:35 ET
Major Shareholder Announcement
2022-06-17 14:38 ET
Genmab Announces Initiation of Share Buy-Back Program
2022-06-11 12:45 ET
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
2022-06-11 12:45 ET
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
2022-06-09 21:17 ET
Genmab Commences New Arbitration Under License Agreement With Janssen
2022-06-09 21:17 ET
Genmab Commences New Arbitration Under License Agreement With Janssen
2022-06-09 18:57 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2022-06-08 18:32 ET
Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-06 15:00 ET
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
2022-06-01 16:21 ET
Major Shareholder Announcement
2022-06-01 16:21 ET
Major Shareholder Announcement
2022-05-26 21:00 ET
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-26 21:00 ET
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-17 18:32 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-05-12 14:00 ET
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
2022-05-12 14:00 ET
Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress
2022-05-11 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2022
2022-05-11 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2022
2022-04-19 10:29 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
2022-04-19 10:29 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
2022-04-13 22:53 ET
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
2022-04-13 21:26 ET
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
2022-04-13 21:25 ET
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
2022-04-13 21:25 ET
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
2022-04-07 23:44 ET
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
2022-04-07 23:44 ET
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
2022-03-29 18:34 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-03-29 18:28 ET
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and Grant of Restricted Stock Units and Warrants to Employees in Genmab
2022-03-29 13:15 ET
Passing of Genmab A/S’ Annual General Meeting
2022-03-14 12:47 ET
Genmab Announces the Nomination of a New Member of the Company’s Board of Directors
2022-03-08 12:31 ET
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
2022-03-08 12:30 ET
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
2022-03-01 14:14 ET
Genmab Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer
2022-02-25 21:19 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-02-25 21:13 ET
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
2022-02-24 15:00 ET
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
2022-02-24 11:01 ET
Notice to Convene the Annual General Meeting of Genmab A/S
2022-02-24 11:01 ET
Notice to Convene the Annual General Meeting of Genmab A/S
2022-02-22 19:11 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-02-16 19:14 ET
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
2022-02-16 16:00 ET
Genmab Publishes 2021 Annual Report
2022-02-16 16:00 ET
Genmab Publishes 2021 Annual Report
2022-01-26 13:44 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-01-25 20:30 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2022-01-25 11:30 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
2022-01-25 11:30 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
2022-01-04 14:00 ET
Genmab and Synaffix Enter into License Agreement for ADC Technology
2022-01-04 14:00 ET
Genmab and Synaffix Enter into License Agreement for ADC Technology
2022-01-04 14:00 ET
Genmab and Synaffix Enter into License Agreement for ADC Technology
2022-01-03 23:38 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-01-03 12:19 ET
Genmab to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-14 18:06 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-12-13 08:28 ET
Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base
2021-11-22 20:59 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-11-22 20:53 ET
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
2021-11-16 18:11 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-11-10 16:00 ET
Genmab Announces Financial Results for the First Nine Months of 2021
2021-11-10 16:00 ET
Genmab Announces Financial Results for the First Nine Months of 2021
2021-11-04 20:24 ET
Genmab Improves its 2021 Financial Guidance
2021-11-04 20:24 ET
Genmab Improves its 2021 Financial Guidance
2021-11-04 13:06 ET
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
2021-11-04 13:05 ET
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
2021-11-03 14:18 ET
Genmab to Present at Jefferies Virtual London Healthcare Conference
2021-10-19 10:29 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
2021-10-19 10:29 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
2021-10-15 17:05 ET
Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
2021-10-07 18:55 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2021-10-01 12:00 ET
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
2021-09-21 18:22 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-09-21 18:22 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-09-20 21:00 ET
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
2021-09-20 21:00 ET
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
2021-09-19 15:30 ET
Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
2021-09-09 11:00 ET
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
2021-09-09 11:00 ET
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet
2021-09-09 11:00 ET
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
2021-08-27 08:42 ET
Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-17 18:51 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-08-11 15:01 ET
Genmab Announces Financial Results for the First Half of 2021
2021-08-11 15:01 ET
Genmab Announces Financial Results for the First Half of 2021
2021-07-21 16:58 ET
Major Shareholder Announcement
2021-07-21 16:58 ET
Major Shareholder Announcement
2021-07-21 10:31 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
2021-07-21 10:31 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
2021-07-06 18:04 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-07-01 07:42 ET
Completion of share buy-back program
2021-06-22 20:16 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2021-06-22 14:12 ET
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-06-22 14:12 ET
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-06-21 07:46 ET
Transactions in connection with share buy-back program
2021-06-10 13:53 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-06-07 08:01 ET
Transactions in connection with share buy-back program
2021-06-02 12:00 ET
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
2021-06-01 10:27 ET
Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-25 07:57 ET
Transactions in connection with share buy-back program
2021-05-21 19:03 ET
Genmab Announces that Janssen has been Granted U.S. FDA Approval for RYBREVANT™ (amivantamab-vmjw) for Patients with Metastatic Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
2021-05-21 13:08 ET
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-05-21 13:08 ET
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-05-19 21:01 ET
Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
2021-05-19 10:41 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-05-11 18:43 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-05-10 07:55 ET
Transactions in connection with share buy-back program
2021-05-05 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2021
2021-05-05 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2021
2021-05-03 18:58 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-04-26 07:18 ET
Transactions in connection with share buy-back program
2021-04-20 10:34 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
2021-04-20 10:34 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
2021-04-13 20:44 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-04-13 20:39 ET
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab
2021-04-13 13:26 ET
Passing of Genmab A/S’ Annual General Meeting
2021-04-12 07:54 ET
Transactions in connection with share buy-back program
2021-04-09 20:00 ET
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
2021-04-09 20:00 ET
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
2021-03-30 05:21 ET
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2021-03-30 05:21 ET
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2021-03-29 15:19 ET
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
2021-03-29 07:12 ET
Transactions in connection with share buy-back program
2021-03-15 08:46 ET
Transactions in connection with share buy-back program
2021-03-10 22:37 ET
Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
2021-03-09 09:14 ET
Notice to Convene the Annual General Meeting of Genmab A/S
2021-03-07 11:39 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-03-02 20:26 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-03-01 09:03 ET
Transactions in connection with share buy-back program
2021-02-26 21:08 ET
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
2021-02-25 19:53 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-02-25 19:53 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-02-23 16:05 ET
Genmab announces initiation of share buy-back program
2021-02-23 16:05 ET
Genmab announces initiation of share buy-back program
2021-02-23 16:00 ET
Genmab Publishes 2020 Annual Report
2021-02-23 16:00 ET
Genmab Publishes 2020 Annual Report
2021-02-22 13:00 ET
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines
2021-02-22 13:00 ET
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines
2021-02-10 21:05 ET
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
2021-02-10 21:05 ET
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
2021-01-29 17:10 ET
CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
2021-01-29 17:10 ET
CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
2021-01-28 21:56 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2021-01-27 14:50 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-01-26 11:45 ET
Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
2021-01-26 11:45 ET
Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
2021-01-15 19:17 ET
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-01-15 19:17 ET
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-01-13 14:20 ET
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
2021-01-13 14:20 ET
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
2021-01-06 15:15 ET
Genmab to Present at the 39th Annual J.P. Morgan Healthcare Conference
2021-01-05 01:26 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-01-04 19:00 ET
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
2020-12-15 22:09 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2020-12-15 22:01 ET
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
2020-12-03 16:41 ET
Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer
2020-11-24 15:40 ET
Genmab Announces Enapotamab Vedotin Update
2020-11-24 15:40 ET
Genmab Announces Enapotamab Vedotin Update
2020-11-19 12:00 ET
ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease
2020-11-10 19:57 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2020-11-10 12:59 ET
Genmab to Present at Jefferies Virtual London Healthcare Conference
2020-11-05 13:39 ET
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
2020-11-05 13:38 ET
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
2020-11-05 11:26 ET
Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosis
2020-11-04 16:04 ET
Genmab Announces Financial Results for the First Nine Months of 2020
2020-11-04 16:04 ET
Genmab Announces Financial Results for the First Nine Months of 2020
2020-11-04 15:13 ET
Genmab Announces Data to be Presented at 2020 ASH Annual Meeting
2020-10-30 11:15 ET
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
2020-10-30 11:15 ET
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
2020-10-21 20:48 ET
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis
2020-10-21 20:48 ET
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis
2020-10-15 13:02 ET
Genmab to Host Capital Markets Day
2020-10-13 10:42 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
2020-10-13 10:41 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
2020-10-07 21:13 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2020-09-29 19:48 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2020-09-29 19:36 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2020-09-22 21:04 ET
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
2020-09-22 21:04 ET
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
2020-09-21 14:20 ET
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
2020-09-21 14:20 ET
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
2020-09-10 12:06 ET
Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis
2020-09-09 12:47 ET
Genmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference
2020-08-26 22:05 ET
Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
2020-08-20 20:40 ET
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
2020-08-20 20:40 ET
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
2020-08-20 20:06 ET
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
2020-08-20 20:06 ET
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
2020-08-20 17:33 ET
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2020-08-20 17:33 ET
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2020-08-18 19:40 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2020-08-12 15:23 ET
Genmab Announces Financial Results for the First Half of 2020
2020-08-12 15:23 ET
Genmab Announces Financial Results for the First Half of 2020
2020-07-31 19:38 ET
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
2020-07-31 19:38 ET
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
2020-07-20 15:57 ET
Major Shareholder Announcement
2020-07-20 15:57 ET
Major Shareholder Announcement
2020-07-16 10:43 ET
Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
2020-07-16 10:43 ET
Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
2020-07-07 11:01 ET
Major Shareholder Announcement
2020-07-03 07:51 ET
Major Shareholder Announcement
2020-07-03 07:51 ET
Major Shareholder Announcement

SEC forms

Show financial reports only

SEC form 6
2026-10-23 15:58 ET
Genmab published news for 2026 q3
SEC form 6
2026-10-23 15:58 ET
Genmab published news for 2026 q3
SEC form 6
2026-10-13 11:50 ET
Genmab published news for 2026 q3
SEC form 6
2026-10-13 11:50 ET
Genmab published news for 2026 q3
SEC form 6
2026-10-07 16:27 ET
Genmab published news for 2026 q3
SEC form 6
2026-10-07 16:27 ET
Genmab published news for 2026 q3
SEC form 6
2026-10-05 19:28 ET
Genmab published news for 2026 q3
SEC form 6
2026-10-05 19:28 ET
Genmab published news for 2026 q3
SEC form 6
2026-10-02 17:51 ET
Genmab published news for 2026 q3
SEC form 6
2026-10-02 17:51 ET
Genmab published news for 2026 q3
SEC form 6
2026-09-29 14:40 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-29 14:40 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-24 18:45 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-24 18:45 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-09 14:43 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-09 14:43 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-08 21:57 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-08 21:57 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-08 11:47 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-08 11:47 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-08 11:47 ET
Genmab published news for 2026 q2
SEC form 6
2026-09-08 11:47 ET
Genmab published news for 2026 q2
SEC form 6
2026-08-12 13:49 ET
Genmab published news for 2026 q2
SEC form 6
2026-08-12 13:49 ET
Genmab published news for 2026 q2
SEC form 6
2026-08-11 18:14 ET
Genmab published news for 2026 q2
SEC form 6
2026-08-11 18:14 ET
Genmab published news for 2026 q2
SEC form 6
2026-08-06 15:08 ET
Genmab reported for 2026 q2
SEC form 6
2026-07-15 11:22 ET
Genmab published news for 2026 q2
SEC form 6
2026-07-15 11:22 ET
Genmab published news for 2026 q2
SEC form 6
2026-06-29 20:24 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-29 20:24 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-17 15:30 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-17 15:30 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-16 19:37 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-16 19:37 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-15 16:08 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-15 16:08 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-15 16:08 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-15 15:08 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-15 15:08 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-11 17:58 ET
Genmab published news for 2026 q1
SEC form 6
2026-06-11 17:58 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-29 20:41 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-29 20:41 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-13 14:15 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-13 14:15 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-12 17:53 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-12 17:53 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-08 20:17 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-08 20:17 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-08 20:17 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-07 15:06 ET
Genmab published news for 2026 q1
SEC form 6
2026-05-07 15:06 ET
Genmab reported for 2026 q1
SEC form 6
2026-04-17 16:20 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-17 16:20 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-17 15:24 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-17 15:24 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-14 16:01 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-14 16:01 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-14 16:01 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-14 12:26 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-14 12:26 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-01 19:21 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-01 19:21 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-01 18:44 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-01 18:44 ET
Genmab published news for 2026 q1
SEC form 6
2026-04-01 18:44 ET
Genmab published news for 2026 q1
SEC form 6
2026-03-30 21:29 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-30 21:29 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-30 21:29 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-23 14:04 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-23 14:04 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-19 18:34 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-19 18:34 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-19 14:29 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-19 14:29 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-16 14:15 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-16 14:15 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-09 14:16 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-09 14:16 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-04 16:32 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-04 16:32 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-02 23:41 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-02 23:41 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-02 14:50 ET
Genmab published news for 2025 q4
SEC form 6
2026-03-02 14:50 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-27 16:16 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-27 16:16 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-27 16:16 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-25 15:51 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-25 15:51 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-24 20:29 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-24 20:29 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-23 15:31 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-23 15:31 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-20 15:07 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-20 15:07 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-18 15:07 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-18 15:07 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-17 20:24 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-17 20:24 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 20
2026-02-17 16:17 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-03 11:59 ET
Genmab published news for 2025 q4
SEC form 6
2026-02-03 11:59 ET
Genmab published news for 2025 q4
SEC form 6
2026-01-29 18:32 ET
Genmab published news for 2025 q4
SEC form 6
2026-01-29 18:32 ET
Genmab published news for 2025 q4
SEC form 6
2026-01-21 12:02 ET
Genmab published news for 2025 q4
SEC form 6
2026-01-21 12:02 ET
Genmab published news for 2025 q4
SEC form 6
2026-01-16 13:41 ET
Genmab published news for 2025 q4
SEC form 6
2026-01-16 13:41 ET
Genmab published news for 2025 q4
SEC form 6
2025-12-29 13:27 ET
Genmab published news for 2025 q3
SEC form 6
2025-12-29 13:27 ET
Genmab published news for 2025 q3
SEC form 6
2025-12-12 07:00 ET
Genmab published news for 2025 q3
SEC form 6
2025-12-12 07:00 ET
Genmab published news for 2025 q3
SEC form 6
2025-12-01 16:46 ET
Genmab published news for 2025 q3
SEC form 6
2025-12-01 16:46 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-26 12:04 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-26 12:04 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-20 15:22 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-20 15:22 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-19 14:35 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-19 14:35 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-19 12:48 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-19 12:48 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-18 15:04 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-18 15:04 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-18 12:10 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-18 12:10 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-12 16:28 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-12 16:28 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-12 16:28 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-12 16:28 ET
Genmab reported for 2025 q3
SEC form 6
2025-11-12 16:28 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-12 16:28 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-06 11:11 ET
Genmab published news for 2025 q3
SEC form 6
2025-11-06 11:11 ET
Genmab reported for 2025 q3
SEC form 6
2025-10-16 19:30 ET
Genmab published news for 2025 q3
SEC form 6
2025-10-16 19:30 ET
Genmab published news for 2025 q3
SEC form 6
2025-09-30 15:27 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-30 15:27 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-29 10:08 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-29 10:08 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-25 19:16 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-25 19:16 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-23 14:56 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-23 14:56 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-23 14:56 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-10 16:01 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-10 16:01 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-09 19:02 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-09 19:02 ET
Genmab published news for 2025 q2
SEC form 6
2025-09-09 19:02 ET
Genmab published news for 2025 q2
SEC form 6
2025-08-13 14:35 ET
Genmab published news for 2025 q2
SEC form 6
2025-08-13 14:35 ET
Genmab published news for 2025 q2
SEC form 6
2025-08-12 19:11 ET
Genmab published news for 2025 q2
SEC form 6
2025-08-12 19:11 ET
Genmab published news for 2025 q2
SEC form 6
2025-08-07 15:38 ET
Genmab reported for 2025 q2
SEC form 6
2025-08-07 14:33 ET
Genmab published news for 2025 q2
SEC form 6
2025-08-07 14:33 ET
Genmab published news for 2025 q2
SEC form 6
2025-07-16 11:15 ET
Genmab published news for 2025 q2
SEC form 6
2025-07-16 11:15 ET
Genmab published news for 2025 q2
SEC form 6
2025-06-30 14:38 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-30 14:38 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-30 14:38 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-23 14:49 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-23 14:49 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-23 14:49 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-18 15:24 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-18 15:24 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-17 18:08 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-17 18:08 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-17 15:53 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-17 15:53 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-16 15:43 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-16 15:43 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-16 14:10 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-16 14:10 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-16 14:10 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-12 17:23 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-12 17:23 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-10 11:27 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-10 11:27 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-10 11:27 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-02 12:42 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-02 12:42 ET
Genmab published news for 2025 q1
SEC form 6
2025-06-02 12:42 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-27 13:19 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-27 13:19 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-27 13:19 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-21 15:31 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-21 15:31 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-20 16:07 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-20 16:07 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-19 16:01 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-19 16:01 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-19 16:01 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-12 13:57 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-12 13:57 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-12 13:57 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-08 15:19 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-08 15:19 ET
Genmab reported for 2025 q1
SEC form 6
2025-05-05 15:05 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-05 15:05 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-05 15:05 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-02 00:21 ET
Genmab published news for 2025 q1
SEC form 6
2025-05-02 00:21 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-28 14:22 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-28 14:22 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-28 14:22 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-22 12:56 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-22 12:56 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-22 12:56 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-15 14:32 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-15 14:32 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-14 16:32 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-14 16:32 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-14 16:32 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-14 16:32 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-10 17:38 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-10 17:38 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-10 16:26 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-10 16:26 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-07 15:01 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-07 15:01 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-07 15:01 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-07 15:01 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-01 20:05 ET
Genmab published news for 2025 q1
SEC form 6
2025-04-01 20:05 ET
Genmab published news for 2025 q1
SEC form 6
2025-03-31 15:26 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-31 15:26 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-31 15:26 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-25 21:30 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-25 21:30 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-24 12:25 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-24 12:25 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-20 15:32 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-20 15:32 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-12 18:27 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-12 18:27 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-12 18:27 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-12 14:47 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-12 14:47 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-10 14:47 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-10 14:47 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-06 16:09 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-06 16:09 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-04 17:20 ET
Genmab published news for 2024 q4
SEC form 6
2025-03-04 17:20 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-28 21:08 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-28 21:08 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-28 21:08 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-26 14:46 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-26 14:46 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-25 19:38 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-25 19:38 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-13 18:05 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-13 18:05 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 20
2025-02-12 13:06 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-12 11:20 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-12 11:20 ET
Genmab published news for 2024 q4
SEC form 6
2025-02-12 11:20 ET
Genmab published news for 2024 q4
SEC form 6
2025-01-29 17:00 ET
Genmab published news for 2024 q4
SEC form 6
2025-01-29 17:00 ET
Genmab published news for 2024 q4
SEC form 6
2024-12-04 11:26 ET
Genmab published news for 2024 q3
SEC form 6
2024-12-04 11:26 ET
Genmab published news for 2024 q3
SEC form 6
2024-12-03 16:45 ET
Genmab published news for 2024 q3
SEC form 6
2024-12-03 16:45 ET
Genmab published news for 2024 q3
SEC form 6
2024-12-03 11:19 ET
Genmab published news for 2024 q3
SEC form 6
2024-12-03 11:19 ET
Genmab published news for 2024 q3
SEC form 6
2024-11-27 12:54 ET
Genmab published news for 2024 q3
SEC form 6
2024-11-27 12:54 ET
Genmab published news for 2024 q3
SEC form 6
2024-11-21 14:56 ET
Genmab published news for 2024 q3
SEC form 6
2024-11-21 14:56 ET
Genmab published news for 2024 q3
SEC form 6
2024-11-06 11:11 ET
Genmab published news for 2024 q3
SEC form 6
2024-11-06 11:11 ET
Genmab reported for 2024 q3
SEC form 6
2024-10-15 10:34 ET
Genmab published news for 2024 q3
SEC form 6
2024-10-15 10:34 ET
Genmab published news for 2024 q3
SEC form 6
2024-10-04 15:16 ET
Genmab published news for 2024 q3
SEC form 6
2024-10-04 15:16 ET
Genmab published news for 2024 q3
SEC form 6
2024-10-01 10:33 ET
Genmab published news for 2024 q3
SEC form 6
2024-10-01 10:33 ET
Genmab published news for 2024 q3
SEC form 6
2024-09-10 16:16 ET
Genmab published news for 2024 q2
SEC form 6
2024-09-10 16:16 ET
Genmab published news for 2024 q2
SEC form 6
2024-08-08 11:14 ET
Genmab published news for 2024 q2
SEC form 6
2024-08-08 11:14 ET
Genmab reported for 2024 q2
SEC form 6
2024-08-08 11:07 ET
Genmab published news for 2024 q2
SEC form 6
2024-08-08 11:07 ET
Genmab published news for 2024 q2
SEC form 6
2024-08-05 06:28 ET
Genmab published news for 2024 q2
SEC form 6
2024-08-05 06:28 ET
Genmab published news for 2024 q2
SEC form 6
2024-07-17 10:00 ET
Genmab published news for 2024 q2
SEC form 6
2024-07-17 10:00 ET
Genmab published news for 2024 q2
SEC form 6
2024-06-28 08:06 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-28 08:06 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-27 17:01 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-27 17:01 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-27 17:01 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-27 10:02 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-27 10:02 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-24 15:13 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-24 15:13 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-24 15:13 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-20 10:54 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-20 10:54 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-18 15:46 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-18 15:46 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-17 20:26 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-17 20:26 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-17 20:26 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-17 10:01 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-17 10:01 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-12 15:50 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-12 15:50 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-11 15:30 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-11 15:30 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-10 12:51 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-10 12:51 ET
Genmab published news for 2024 q1
SEC form 6
2024-06-10 12:51 ET
Genmab published news for 2024 q1
SEC form 6
2024-05-02 11:08 ET
Genmab published news for 2024 q1
SEC form 6
2024-05-02 11:08 ET
Genmab reported for 2024 q1
SEC form 6
2024-04-29 19:10 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-29 19:10 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-29 10:22 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-29 10:22 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-29 10:22 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-22 16:14 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-22 16:14 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-22 16:14 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-16 10:07 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-16 10:07 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-15 13:17 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-15 13:17 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-15 13:17 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-08 13:41 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-08 13:41 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-08 13:41 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-03 06:19 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-03 06:19 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-02 09:10 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-02 09:10 ET
Genmab published news for 2024 q1
SEC form 6
2024-04-02 09:10 ET
Genmab published news for 2024 q1
SEC form 6
2024-03-25 14:13 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-25 14:13 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-25 14:13 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-21 15:28 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-21 15:28 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-18 16:37 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-18 16:37 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-18 16:37 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-15 09:46 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-15 09:46 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-13 17:10 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-13 17:10 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-13 17:10 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-13 11:34 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-13 11:34 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-11 13:43 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-11 13:43 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-11 13:43 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-04 13:50 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-04 13:50 ET
Genmab reported for 2023 q4
SEC form 6
2024-03-04 13:26 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-04 13:26 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-04 13:26 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-01 18:38 ET
Genmab published news for 2023 q4
SEC form 6
2024-03-01 18:38 ET
Genmab published news for 2023 q4
SEC form 6
2024-02-14 00:00 ET
Genmab published news for 2023 q4
SEC form 6
2024-02-14 00:00 ET
Genmab published news for 2023 q4
SEC form 6
2024-02-14 00:00 ET
Genmab published news for 2023 q4
SEC form 6
2023-11-08 12:24 ET
Genmab published news for 2023 q3
SEC form 6
2023-11-07 11:12 ET
Genmab reported for 2023 q3
SEC form 6
2023-10-17 08:22 ET
Genmab published news for 2023 q3
SEC form 6
2023-10-05 10:35 ET
Genmab published news for 2023 q3
SEC form 6
2023-09-28 16:15 ET
Genmab published news for 2023 q2
SEC form 6
2023-09-25 08:53 ET
Genmab published news for 2023 q2
SEC form 6
2023-09-13 09:59 ET
Genmab published news for 2023 q2
SEC form 6
2023-09-12 15:05 ET
Genmab published news for 2023 q2
SEC form 6
2023-09-05 09:12 ET
Genmab published news for 2023 q2
SEC form 6
2023-08-03 11:16 ET
Genmab published news for 2023 q2
SEC form 6
2023-07-27 18:15 ET
Genmab published news for 2023 q2
SEC form 6
2023-07-21 09:08 ET
Genmab published news for 2023 q2
SEC form 6
2023-07-20 09:00 ET
Genmab published news for 2023 q2
SEC form 6
2023-06-27 18:54 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-21 11:18 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-20 15:58 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-20 12:57 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-08 17:27 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-01 16:24 ET
Genmab published news for 2023 q1
SEC form 6
2023-05-31 09:44 ET
Genmab published news for 2023 q1
SEC form 6
2023-05-24 10:46 ET
Genmab published news for 2023 q1
SEC form 6
2023-05-23 15:26 ET
Genmab published news for 2023 q1
SEC form 6
2023-04-18 10:20 ET
Genmab published news for 2023 q1
SEC form 6
2023-04-06 16:52 ET
Genmab reported for 2023 q1
SEC form 6
2023-04-03 17:18 ET
Genmab published news for 2023 q1
SEC form 6
2023-04-03 11:14 ET
Genmab published news for 2023 q1
SEC form 6
2023-04-03 09:46 ET
Genmab published news for 2023 q1
SEC form 6
2023-03-29 16:32 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-29 10:05 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-27 10:58 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-20 11:10 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-13 11:53 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-06 12:14 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-01 10:47 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-28 16:32 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-28 10:49 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-27 13:46 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-24 16:11 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-23 13:46 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-22 15:51 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-22 12:55 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-22 11:48 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-22 00:00 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-30 11:39 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-24 14:33 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-24 08:49 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-19 11:55 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-03 12:55 ET
Genmab published news for 2022 q4
SEC form 6
2022-12-14 15:50 ET
Genmab published news for 2022 q3
SEC form 6
2022-12-14 09:02 ET
Genmab published news for 2022 q3
SEC form 6
2022-12-13 15:54 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-29 10:33 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-23 15:14 ET
Genmab reported for 2022 q3
SEC form 6
2022-11-21 14:55 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-16 10:19 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-15 14:05 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-14 13:52 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-09 11:31 ET
Genmab reported for 2022 q3
SEC form 6
2022-11-03 13:55 ET
Genmab published news for 2022 q3
SEC form 6
2022-10-18 08:48 ET
Genmab published news for 2022 q3
SEC form 6
2022-10-05 16:11 ET
Genmab published news for 2022 q3
SEC form 6
2022-09-28 09:21 ET
Genmab published news for 2022 q2
SEC form 6
2022-09-27 12:51 ET
Genmab published news for 2022 q2
SEC form 6
2022-09-26 09:30 ET
Genmab published news for 2022 q2
SEC form 6
2022-09-20 15:31 ET
Genmab published news for 2022 q2
SEC form 6
2022-09-01 12:41 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-29 09:38 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-24 15:04 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-22 09:05 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-17 13:33 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-17 10:48 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-16 14:40 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-15 09:14 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-10 00:00 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-08 12:49 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-08 08:29 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-02 15:08 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-01 10:42 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-25 08:40 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-20 14:02 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-19 08:14 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-18 11:08 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-18 09:27 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-11 12:10 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-11 10:35 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-06 09:06 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-05 14:11 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-05 10:29 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-01 12:23 ET
Genmab published news for 2022 q2
SEC form 6
2022-06-30 14:32 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-27 10:24 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-23 12:02 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-21 08:33 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-17 11:01 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-16 09:06 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-09 17:22 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-09 15:19 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-01 12:37 ET
Genmab published news for 2022 q1
SEC form 6
2022-05-18 10:52 ET
Genmab published news for 2022 q1
SEC form 6
2022-05-17 14:39 ET
Genmab published news for 2022 q1
SEC form 6
2022-05-11 11:24 ET
Genmab published news for 2022 q1
SEC form 6
2022-04-19 08:08 ET
Genmab published news for 2022 q1
SEC form 6
2022-04-13 17:28 ET
Genmab published news for 2022 q1
SEC form 6
2022-04-07 20:09 ET
Genmab published news for 2022 q1
SEC form 6
2022-04-07 09:23 ET
Genmab published news for 2022 q1
SEC form 6
2022-03-29 14:58 ET
Genmab published news for 2021 q4
SEC form 6
2022-03-29 09:37 ET
Genmab published news for 2021 q4
SEC form 6
2022-03-14 09:58 ET
Genmab published news for 2021 q4
SEC form 6
2022-03-09 10:14 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-25 16:35 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-24 09:15 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-23 11:28 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-22 14:21 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-16 13:56 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-16 00:00 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-03 10:18 ET
Genmab published news for 2021 q4
SEC form 6
2022-01-26 09:45 ET
Genmab published news for 2021 q4
SEC form 6
2022-01-25 15:43 ET
Genmab published news for 2021 q4
SEC form 6
2022-01-25 08:39 ET
Genmab published news for 2021 q4
SEC form 6
2022-01-03 18:46 ET
Genmab published news for 2021 q4
SEC form 6
2021-12-15 08:40 ET
Genmab published news for 2021 q3
SEC form 6
2021-12-14 13:23 ET
Genmab published news for 2021 q3
SEC form 6
2021-12-01 10:07 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-22 16:09 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-17 12:02 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-16 13:22 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-10 12:01 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-04 17:23 ET
Genmab published news for 2021 q3
SEC form 6
2021-10-19 10:28 ET
Genmab published news for 2021 q3
SEC form 6
2021-10-15 10:27 ET
Genmab published news for 2021 q3
SEC form 6
2021-10-07 15:04 ET
Genmab published news for 2021 q3
SEC form 6
2021-09-22 08:53 ET
Genmab published news for 2021 q2
SEC form 6
2021-09-21 14:35 ET
Genmab published news for 2021 q2
SEC form 6
2021-09-20 17:16 ET
Genmab published news for 2021 q2
SEC form 6
2021-08-18 13:13 ET
Genmab published news for 2021 q2
SEC form 6
2021-08-17 15:03 ET
Genmab published news for 2021 q2
SEC form 6
2021-08-11 00:00 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-21 14:13 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-21 08:39 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-07 09:01 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-06 14:17 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-01 09:54 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-01 09:34 ET
Genmab published news for 2021 q2
SEC form 6
2021-06-28 09:59 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-22 16:47 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-22 11:22 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-21 09:35 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-15 21:52 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-14 09:17 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-10 11:05 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-07 10:46 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-01 11:04 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-25 10:13 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-21 09:49 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-21 09:28 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-19 09:30 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-17 11:32 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-12 16:14 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-12 12:44 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-11 15:36 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-10 10:25 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-07 16:33 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-05 12:54 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-03 15:16 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-03 13:02 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-26 17:00 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-26 11:39 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-20 10:47 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-19 10:10 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-15 15:15 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-13 16:54 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-13 09:53 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-12 09:47 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-09 16:32 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-06 12:15 ET
Genmab published news for 2021 q1
SEC form 6
2021-03-30 09:54 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-29 11:07 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-29 10:28 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-22 14:19 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-15 13:55 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-09 09:25 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-08 11:49 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-08 10:25 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-03 11:42 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-02 16:09 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-02 14:47 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-01 10:14 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-26 16:24 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-25 16:40 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-23 14:30 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-23 12:38 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-22 09:53 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-10 17:05 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-05 10:54 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-29 14:39 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-28 17:26 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-27 11:06 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-26 10:14 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-15 15:23 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-13 09:59 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-04 21:11 ET
Genmab published news for 2020 q4
SEC form 6
2020-12-21 10:25 ET
Genmab published news for 2020 q3
SEC form 6
2020-12-15 17:17 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-24 11:59 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-12 09:54 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-10 15:04 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-05 11:06 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-04 11:48 ET
Genmab published news for 2020 q3
SEC form 6
2020-10-21 17:06 ET
Genmab published news for 2020 q3
SEC form 6
2020-10-15 11:09 ET
Genmab published news for 2020 q3
SEC form 6
2020-10-14 16:54 ET
Genmab published news for 2020 q3
SEC form 6
2020-10-07 17:15 ET
Genmab published news for 2020 q3
SEC form 6
2020-09-30 14:06 ET
Genmab published news for 2020 q2
SEC form 6
2020-09-30 10:49 ET
Genmab published news for 2020 q2
SEC form 6
2020-09-29 17:49 ET
Genmab published news for 2020 q2